Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein.

Mandal RS, Panda S, Das S.

J Biomol Struct Dyn. 2018 Mar;36(4):966-980. doi: 10.1080/07391102.2017.1305295. Epub 2017 Apr 10.

PMID:
28279127
2.

Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.

Li L, Li Y, Zhang L, Hou T.

J Chem Inf Model. 2012 Oct 22;52(10):2715-29. doi: 10.1021/ci300375k. Epub 2012 Oct 2.

PMID:
22998323
3.

Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.

Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, Gramer MR, Swafford S, DeLiberto T, Govorkova EA, Webster RG.

J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.

4.

Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.

Woods CJ, Malaisree M, Pattarapongdilok N, Sompornpisut P, Hannongbua S, Mulholland AJ.

Biochemistry. 2012 May 29;51(21):4364-75. doi: 10.1021/bi300561n. Epub 2012 May 17.

PMID:
22574858
5.

H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.

van der Vries E, Collins PJ, Vachieri SG, Xiong X, Liu J, Walker PA, Haire LF, Hay AJ, Schutten M, Osterhaus AD, Martin SR, Boucher CA, Skehel JJ, Gamblin SJ.

PLoS Pathog. 2012 Sep;8(9):e1002914. doi: 10.1371/journal.ppat.1002914. Epub 2012 Sep 20.

6.

Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.

Pan P, Li L, Li Y, Li D, Hou T.

Antiviral Res. 2013 Nov;100(2):356-64. doi: 10.1016/j.antiviral.2013.09.006. Epub 2013 Sep 19.

PMID:
24055835
7.

Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.

Meeprasert A, Khuntawee W, Kamlungsua K, Nunthaboot N, Rungrotmongkol T, Hannongbua S.

J Mol Graph Model. 2012 Sep;38:148-54. doi: 10.1016/j.jmgm.2012.06.007. Epub 2012 Jul 4.

PMID:
23079644
8.
9.

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

McKimm-Breschkin JL.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:25-36. doi: 10.1111/irv.12047. Review.

10.

Molecular basis of drug resistance in A/H1N1 virus.

Vergara-Jaque A, Poblete H, Lee EH, Schulten K, González-Nilo F, Chipot C.

J Chem Inf Model. 2012 Oct 22;52(10):2650-6. doi: 10.1021/ci300343w. Epub 2012 Oct 4.

PMID:
22978683
11.

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.

Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV.

J Infect Dis. 2015 Oct 15;212(8):1209-13. doi: 10.1093/infdis/jiv245. Epub 2015 May 5.

PMID:
25943200
12.

Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.

Singh A, Soliman ME.

Drug Des Devel Ther. 2015 Jul 31;9:4137-54. doi: 10.2147/DDDT.S81934. eCollection 2015.

13.

[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F.

Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19. Review. French.

PMID:
20303677
14.

A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.

Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.

Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.

PMID:
23131559
15.

In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.

Liu H, Yao X, Wang C, Han J.

Mol Pharm. 2010 Jun 7;7(3):894-904. doi: 10.1021/mp100041b.

PMID:
20420444
16.

Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.

Correia V, Santos LA, Gíria M, Almeida-Santos MM, Rebelo-de-Andrade H.

J Med Virol. 2015 Jan;87(1):45-56. doi: 10.1002/jmv.23986. Epub 2014 Jul 21.

PMID:
25042157
17.

In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir.

Karthick V, Shanthi V, Rajasekaran R, Ramanathan K.

Protoplasma. 2013 Feb;250(1):197-207. doi: 10.1007/s00709-012-0394-6. Epub 2012 Mar 6.

PMID:
22392098
18.

Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.

Duwe SC, Wedde M, Birkner P, Schweiger B.

Antiviral Res. 2011 Jan;89(1):115-8. doi: 10.1016/j.antiviral.2010.11.001. Epub 2010 Nov 9.

PMID:
21070812
19.

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.

PMID:
19917319
20.

E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.

L'Huillier AG, Abed Y, Petty TJ, Cordey S, Thomas Y, Bouhy X, Schibler M, Simon A, Chalandon Y, van Delden C, Zdobnov E, Boquete-Suter P, Boivin G, Kaiser L.

J Infect Dis. 2015 Dec 1;212(11):1726-34. doi: 10.1093/infdis/jiv288. Epub 2015 May 17.

Supplemental Content

Support Center